Full Fed. Circ. May Blunt On-Sale Bar's Risk To Small Cos.
The full Federal Circuit has a chance to narrow the reach of the on-sale bar after agreeing to review a decision that invalidated patents for the blood-thinning drug Angiomax under a...To view the full article, register now.
Already a subscriber? Click here to view full article